Literature DB >> 30199754

Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine.

Ki-Hye Kim1, Young-Man Kwon1, Young-Tae Lee1, Hye Suk Hwang2, Min-Chul Kim3, Eun-Ju Ko1, Bao-Zhong Wang1, Fu-Shi Quan4, Sang-Moo Kang5.   

Abstract

Current licensed adjuvants including aluminum hydroxide (alum) bias immune responses toward T helper type 2 (Th2) immune responses. We tested whether virus-like particles presenting flagellin (Flag VLP) exhibit adjuvant effects on eliciting Th1 type immune responses and improving the efficacy of poor immunogenic tandem repeat M2e (M2e5x) protein vaccine against influenza virus. Co-immunization of mice with Flag VLP and M2e5x protein vaccine induced significantly higher levels of IgG2a isotype (Th1) antibodies in sera and mucosal sites, effector CD4+ T cells secreting IFN-γ and granzyme B, and more effective lung viral clearance and protection compared to alum adjuvant. Flag VLP stimulated primary macrophages and dendritic cells to secrete inflammatory cytokines, which is partially dependent on the Toll-like receptor 5. This study provides insight into developing effective vaccine adjuvants.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Effector T cells; Granzyme B; Innate immunity; Tandem repeat extracellular domain of M2 (M2e5x); Virus like particles expressing flagellin (Flag VLP)

Mesh:

Substances:

Year:  2018        PMID: 30199754      PMCID: PMC6190693          DOI: 10.1016/j.virol.2018.08.019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  37 in total

1.  Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.

Authors:  Tong-Ming Fu; Karen M Grimm; Michael P Citron; Daniel C Freed; Jiang Fan; Paul M Keller; John W Shiver; Xiaoping Liang; Joseph G Joyce
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

Review 2.  Flagellin as an adjuvant: cellular mechanisms and potential.

Authors:  Steven B Mizel; John T Bates
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

3.  Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.

Authors:  Eun-Ju Ko; Young-Tae Lee; Ki-Hye Kim; Youri Lee; Yu-Jin Jung; Min-Chul Kim; Yu-Na Lee; Taeuk Kang; Sang-Moo Kang
Journal:  J Immunol       Date:  2016-11-23       Impact factor: 5.422

Review 4.  Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Authors:  Barney S Graham
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells.

Authors:  Terry K Means; Fumitaka Hayashi; Kelly D Smith; Alan Aderem; Andrew D Luster
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

6.  Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.

Authors:  Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Richard W Compans
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

7.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

8.  Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response.

Authors:  Arnaud Didierlaurent; Isabel Ferrero; Luc A Otten; Bertrand Dubois; Monique Reinhardt; Harald Carlsen; Rune Blomhoff; Shikuo Akira; Jean-Pierre Kraehenbuhl; Jean-Claude Sirard
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

9.  Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.

Authors:  Eun-Ju Ko; Young-Tae Lee; Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Timothy L Denning; Sang-Moo Kang
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

Review 10.  A "universal" human influenza A vaccine.

Authors:  W Fiers; M De Filette; A Birkett; S Neirynck; W Min Jou
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

View more
  10 in total

1.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

2.  Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.

Authors:  Ki-Hye Kim; Young-Tae Lee; Soojin Park; Yu-Jin Jung; Youri Lee; Eun-Ju Ko; Yu-Jin Kim; Xuguang Li; Sang-Moo Kang
Journal:  Virology       Date:  2019-07-08       Impact factor: 3.616

Review 3.  Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.

Authors:  Fang Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2019-02-06       Impact factor: 4.530

4.  Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development.

Authors:  Yiwen Zhao; Zhuofan Li; Jewel Voyer; Yibo Li; Xinyuan Chen
Journal:  ACS Appl Mater Interfaces       Date:  2022-04-25       Impact factor: 10.383

Review 5.  Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.

Authors:  Mark B Carascal; Rance Derrick N Pavon; Windell L Rivera
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

6.  6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice.

Authors:  Wenli Hou; Lihui Lv; Yihan Wang; Man Xing; Yingying Guo; Di Xie; Xin Wei; Xiuyue Zhang; Hui Liu; Jiling Ren; Dongming Zhou
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

7.  Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice.

Authors:  Yu-Jin Jung; Ki-Hye Kim; Eun-Ju Ko; Youri Lee; Min-Chul Kim; Young-Tae Lee; Cheol-Hyun Kim; Subbiah Jeeva; Bo Ryoung Park; Sang-Moo Kang
Journal:  Vaccine       Date:  2020-07-13       Impact factor: 3.641

Review 8.  Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.

Authors:  Lynda Coughlan; Eric J Kremer; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2022-01-31       Impact factor: 12.910

9.  BCG Cell Wall Skeleton As a Vaccine Adjuvant Protects Both Infant and Old-Aged Mice from Influenza Virus Infection.

Authors:  Ki-Hye Kim; Young-Tae Lee; Yoonsuh Park; Eun-Ju Ko; Yu-Jin Jung; Yu-Jin Kim; Eun-Kyeong Jo; Sang-Moo Kang
Journal:  Biomedicines       Date:  2021-05-05

10.  Progress in the development of virus-like particle vaccines against respiratory viruses.

Authors:  Fu-Shi Quan; Swarnendu Basak; Ki-Back Chu; Sung Soo Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2020-01-18       Impact factor: 5.217

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.